MME and ovarian carcinoma: MME-AS1 and miR-182 have not been reported in ICC according to literature, but miR-182 can inhibit cell proliferation of various cancers, such as ovarian cancer and colorectal cancer [13, 14], suggesting that MME-AS1 may affect the prognosis of patients with ICC by targeting hsa-miR-182.